









Markets
/
Stocks
/
nasdaq-ew
/

Edwards Lifesciences Corp

78.710USD

+0.610+0.78%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

45.71BMarket Cap

33.52P/E TTM



Edwards Lifesciences Corp

78.710

+0.610+0.78%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Edwards Lifesciences Corp

Currency: USD Updated: 2026-02-06

Key Insights

Edwards Lifesciences Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 8 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 96.06.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Edwards Lifesciences Corp's Score

Industry at a Glance

Industry Ranking

8 / 205

Overall Ranking

75 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

28°C



Very Low

Very High

Neutral

Edwards Lifesciences Corp Highlights

StrengthsRisks

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 5.44B.

Fairly Valued

The company’s latest PE is 33.52, at a medium 3-year percentile range.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 7.71K shares of this stock.

Analyst Rating

Based on 35 analysts

Buy

Current Rating

96.057

Target Price

+22.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Edwards Lifesciences Corp is 9.39, ranking 8 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.55B, representing a year-over-year increase of 14.67%, while its net profit experienced a year-over-year increase of 90.52%.

Score

Industry at a Glance

Previous score

9.39

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.19

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.75

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Edwards Lifesciences Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Edwards Lifesciences Corp is 7.01, ranking 133 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 33.52, which is 23.97% below the recent high of 41.55 and 72.19% above the recent low of 9.32.

Score

Industry at a Glance

Previous score

7.01

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 8/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Edwards Lifesciences Corp is 7.83, ranking 109 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 95.50, with a high of 105.00 and a low of 72.00.

Score

Industry at a Glance

Previous score

7.83

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 35 analysts

Buy

Current Rating

96.057

Target Price

+22.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

Danaher Corp

DHR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Edwards Lifesciences Corp is 6.39, ranking 150 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 84.12 and the support level at 75.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.27

Change

0.12

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-1.049

Sell

RSI(14)

34.001

Neutral

STOCH(KDJ)(9,3,3)

14.927

Oversold

ATR(14)

1.975

Low Volatility

CCI(14)

-164.565

Sell

Williams %R

85.494

Oversold

TRIX(12,20)

-0.205

Sell

StochRSI(14)

22.432

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

80.266

Sell

MA10

81.391

Sell

MA20

82.726

Sell

MA50

84.252

Sell

MA100

81.603

Sell

MA200

79.515

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Edwards Lifesciences Corp is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 93.53%, representing a quarter-over-quarter decrease of 0.51%. The largest institutional shareholder is The Vanguard, holding a total of 69.80M shares, representing 12.03% of shares outstanding, with 2.35% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

70.09M

+0.51%

BlackRock Institutional Trust Company, N.A.

30.52M

-1.20%

State Street Investment Management (US)

25.62M

-0.06%

Wellington Management Company, LLP

20.80M

+4.93%

JP Morgan Asset Management

17.92M

-10.80%

Jennison Associates LLC

13.96M

+19.60%

Fidelity Management & Research Company LLC

13.03M

+466.56%

Geode Capital Management, L.L.C.

12.84M

+0.90%

Walter Scott & Partners Ltd.

9.96M

+11.73%

Union Investment Privatfonds GmbH

8.60M

+0.22%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Edwards Lifesciences Corp is 9.31, ranking 12 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.94. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.